last posts

Global Myasthenia Gravis Diagnosis and Treatment Market Report 2022 to 2028 - North America Expected to Hold Huge Market Share -


DUBLIN–(BUSINESS WIRE)–The report “Global Myasthenia Gravis Diagnosis and Treatment Market Forecast, 2022-2028” has been added to from offer.

The global MG diagnosis and treatment market is expected to grow at a substantial CAGR of 7.9% during the forecast period.

Companies cited

  • Amneal Pharmaceuticals, Inc.

  • Argenx SE

  • Astellas Pharma, Inc.

  • Avadel Pharmaceuticals PLC

  • Bausch Health Companies Inc.

  • Baxter International, Inc.

  • CSL Behring

  • CuraVac, Inc.

  • GlaxoSmithKline plc

  • Immunovant, Inc.

  • Mitsubishi Tanabe Pharma Corp.

  • Ra Pharmaceuticals, Inc.

  • Takeda Pharmaceutical Co., Ltd.

  • UCB Pharma

  • Valeant Pharmaceuticals International, Inc.

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes skeletal muscle weakness. The eyes, face and swallowing tubes are the most affected muscles. Rising awareness of rare diseases is growing the market for diagnosis and treatment of myasthenia gravis globally.

This disease is caused by an abnormal immune reaction (antibody-mediated autoimmune response) in which the body’s immune defenses (i.e. antibodies) inappropriately attack certain proteins in the muscles that receive the ‘nerve impulses.

Factors such as antibodies and thymus should be caused by myasthenia gravis. According to the Myasthenia Gravis Foundation Of America, approximately 14-20% of cases per 100,000 population in the United States, or approximately 36,000-60,000 cases in the United States.

Impact of the COVID-19 Pandemic on the Global Myasthenia Gravis (MG) Diagnosis and Treatment Market

During the COVID-19 pandemic, limited transportation options and travel restrictions created hurdles for patients, international trade, and transportation, which disrupted the Myasthenia Gravis diagnosis and treatment market. Hospital patient and doctor attendance has declined during the pandemic which has severely affected the patient and myasthenia gravis diagnosis and treatment market.

Many patients have struggled to get proper medical care due to the pandemic. Diagnosis and treatment have been mostly suspended in hospitals and diagnostic centers. Additionally, many manufacturers have faced supply chain issues and roadblocks during the pandemic.

Sector outlook

The global MG diagnosis and treatment market is segmented on the basis of treatment, diagnosis, and end users. Based on treatment, the market is segmented into drugs, surgery and others. Based on diagnostics, the market is sub-segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostics, imaging and others. Further, based on the end users, the market is expanded to hospitals, clinics, and others.

Among the end users, hospitals are expected to hold a large market share. As patients mainly go to the hospital for the diagnosis and treatment of the disease due to the presence of advanced equipment and proper guidance and consultation related to the disease.

The drugs segment is expected to hold a major share of the global myasthenia gravis (MG) diagnosis and treatment market

The high consumption of drugs to manage the symptoms associated with MG is a key factor contributing to the high market share of this market segment. Immunosuppressive drugs such as tacrolimus and cyclosporine and immunotherapies such as eculizumab and corticosteroids are the main drugs taken by patients with myasthenia gravis. The presence of a strong product portfolio of drugs used in the treatment of myasthenia gravis is expected to drive the growth of this market segment. For example, IVIG treatment provides safe and effective long-term therapy for patients who do not benefit from conventional therapies.

Regional outlook

The global MG diagnosis and treatment market is further segmented on the basis of geography including North America (US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea). , and others), and the rest of the world (the Middle East, Africa and Latin America). The market can be analyzed for a particular region or country as per requirement.

North America is expected to hold a considerable market share over the forecast period. High healthcare expenditures, presence of consistent government policies on R&D related to myasthenia gravis treatment as well as presence of huge patient pool are expected to be major contributing factors for the high share of the North America region . According to the National Organization for Rare Disorders (NORD), approximately 14 to 40 out of every 100,000 people in the United States suffer from myasthenia gravis on an annual basis. These factors will contribute to the growth of the market.

The report covers

  • Market value data analysis of 2021 and forecast till 2028.

  • Annualized market revenue ($millions) for each market segment.

  • Country analysis of major geographic regions.

  • Key companies operating in the global Myasthenia Gravis (MG) Diagnosis and Treatment Market. Based on data availability, information related to new product launches and relevant news is also available in the report.

  • Analysis of business strategies by identifying key market segments positioned for strong growth in the future.

  • Analysis of market entry and expansion strategies.

  • Competitive strategies by identifying “who stands where” in the market.

For more information about this report visit



Font Size
lines height